The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease

YARLIOGLU, Aysenur Miray; Oğuz, Ebru Gök; Gündoğmuş, Ayse Gökçen; Atilgan, Kadir Gokhan; Sahin, Hatice; Aylı, Mehmet Deniz

doi:10.1007/s11255-022-03375-2

Cited by 10 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 Patients with more symptoms are less likely to comply with dietary guidelines, which may negatively affect disease progression, and depression is more common in patients with more severe disease. 17 Patients in the Chronic Renal Insufficiency Cohort were more likely to have rapid nonlinear eGFR decline with moderate or high scores on the Beck Depression Index compared with patients with low scores. 22 …”

Section: Pain and Depressionmentioning

confidence: 95%

See 1 more Smart Citation

Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease

Hogan,

Simmons,

Ullman

et al. 2023

Kidney360

View full text Add to dashboard Cite

Patients with autosomal dominant polycystic kidney disease benefit from specialized care over their lifetimes, starting with diagnosis of the condition with ongoing discussion of both the renal course and extra-renal issues. Both renal and extra-renal issues may continue to cause major morbidity even after successful kidney transplant or initiation of RRT, and extra-renal disease aspects should always be considered as part of routine management. In this review, we will focus on updates in pain/depression screening, cardiac manifestations, liver and pancreatic cysts, kidney stone management, and genetic counseling. In some instances, we have shared our current clinical practice rather than an evidence-based guideline. We anticipate more standardization of care after the release of the Kidney Disease Improving Global Outcomes guidelines for management in autosomal dominant polycystic kidney disease later this year.

show abstract

Section: Pain and Depressionmentioning

confidence: 95%

“…Between 22% and 60% of patients with ADPKD have depression, 15 – 17 and therefore, we also recommend screening. Although providers generally consider early ADPKD to be asymptomatic, the mental impact of an ADPKD diagnosis is immediate.…”

Section: Pain and Depressionmentioning

confidence: 99%

Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease

Hogan,

Simmons,

Ullman

et al. 2023

Kidney360

View full text Add to dashboard Cite

show abstract

“…Advanced CKD stage is negatively correlated with quality of life; and grief, anxiety, depression, and feelings of helplessness are common among those with ADPKD. 77 , 78 Overall, additional research is required to draw concrete conclusions and identify strategies for improving the mental health of patients with ADPKD.…”

Section: Methodsmentioning

confidence: 99%

How Does ADPKD Severity Differ Between Family Members?

Yeung,

Fryml,

Lanktree

2024

Kidney International Reports

View full text Add to dashboard Cite

“…These proteins play a major role in cell physiology due to their influence on different biological pathways, including cell adhesion, differentiation, proliferation, and apoptosis [120,121]. It has been reported that patients suffering from ADPKD tend to have a reduced quality of life, increased psychological risk, reduced physical health, anxiety, and depression [122][123][124]. Currently, a vasopressin V2 receptor antagonist (V2RA) is the sole medication demonstrated to mitigate ADPKD disease progression.…”

Section: Therapeutic Inferences Of Mirnas and Lncrnas In Autosomal Do...mentioning

confidence: 99%

Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases

Bravo-Vázquez,

Paul,

Colín-Jurado

et al. 2024

Genes

View full text Add to dashboard Cite

MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two crucial classes of transcripts that belong to the major group of non-coding RNAs (ncRNAs). These RNA molecules have significant influence over diverse molecular processes due to their crucial role as regulators of gene expression. However, the dysregulated expression of these ncRNAs constitutes a fundamental factor in the etiology and progression of a wide variety of multifaceted human diseases, including kidney diseases. In this context, over the past years, compelling evidence has shown that miRNAs and lncRNAs could be prospective targets for the development of next-generation drugs against kidney diseases as they participate in a number of disease-associated processes, such as podocyte and nephron death, renal fibrosis, inflammation, transition from acute kidney injury to chronic kidney disease, renal vascular changes, sepsis, pyroptosis, and apoptosis. Hence, in this current review, we critically analyze the recent findings concerning the therapeutic inferences of miRNAs and lncRNAs in the pathophysiological context of kidney diseases. Additionally, with the aim of driving advances in the formulation of ncRNA-based drugs tailored for the management of kidney diseases, we discuss some of the key challenges and future prospects that should be addressed in forthcoming investigations.

show abstract

The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease

Cited by 10 publications

References 38 publications

Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease

Beyond Loss of Kidney Function: Patient Care in Autosomal Dominant Polycystic Kidney Disease

How Does ADPKD Severity Differ Between Family Members?

Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases

Contact Info

Product

Resources

About